PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
15901801-1	2005	Our previous study showed that rilmenidine, a selective I(1)-imidazoline receptor agonist, enhanced the phosphorylation of mitogen-activated protein kinase (MAPK)(p42/44), via the phosphatidylcholine-specific phospholipase C pathway in the pheochromocytoma cell line (PC12).	Rilmenidine	31-42	mitogen activated protein kinase 3	Rattus norvegicus	157-161	
15901801-7	2005	An increase in RVLM MAPK(p42/44) occurred only after rilmenidine.	Rilmenidine	53-64	mitogen activated protein kinase 3	Rattus norvegicus	20-24	
11274989-4	2001	The Western blotting analysis showed that rilmenidine (10 microM) produced a time-dependent activation of p42(mapk) and p44(mapk) that reached its maximum at 15 min and returned to control levels after 30 min.	Rilmenidine	42-53	mitogen activated protein kinase 3	Rattus norvegicus	120-123